Enliven Therapeutics
ELVN
31 hedge funds and large institutions have $8.78M invested in Enliven Therapeutics in 2022 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 4 increasing their positions, 7 reducing their positions, and 7 closing their positions.
71% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 7
19% more funds holding
Funds holding: 26 → 31 (+5)
13% more capital invested
Capital invested by funds: $7.76M → $8.78M (+$1.02M)
2.29% less ownership
Funds ownership: 10.12% → 7.83% (-2.3%)
43% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 7
66% less call options, than puts
Call options by funds: $939K | Put options by funds: $2.73M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JC
JBF Capital
Aspen,
Colorado
|
+$310K |
| 2 |
CM
Caption Management
Oklahoma City,
Oklahoma
|
+$251K |
| 3 |
JG
Jefferies Group
New York
|
+$154K |
| 4 |
Parallax Volatility Advisers
San Francisco,
California
|
+$146K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$141K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NMC
NEA Management Company
Timonium,
Maryland
|
-$1.23M |
| 2 |
LPC
Lion Point Capital
New York
|
-$1.14M |
| 3 |
Goldman Sachs
New York
|
-$1.06M |
| 4 |
Two Sigma Advisers
New York
|
-$223K |
| 5 |
Two Sigma Investments
New York
|
-$145K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AWM
26
AE Wealth Management
Topeka,
Kansas
| $23K | +$14.8K | +2,500 | New |
|
|
O
27
OrbiMed
New York
| $10K | – | – | – |
|
28
Federated Hermes
Pittsburgh,
Pennsylvania
| $4K | -$3.2K | -542 | -58% |
|
|
NMC
29
NEA Management Company
Timonium,
Maryland
| – | -$1.23M | -251,681 | Closed |
|
|
30
Goldman Sachs
New York
| – | -$1.06M | -218,145 | Closed |
|
|
LPC
31
Lion Point Capital
New York
| – | -$1.14M | -208,695 | Closed |
|
|
32
Two Sigma Advisers
New York
| – | -$223K | -45,700 | Closed |
|
|
33
Two Sigma Investments
New York
| – | -$145K | -29,784 | Closed |
|
34
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$145K | -24,552 | Closed |
|
|
PAM
35
Panagora Asset Management
Boston,
Massachusetts
| – | -$14K | -2,863 | Closed |
|
36
JP Morgan Chase
New York
| – | +$12 | +2 | New |
|
37
Wells Fargo
San Francisco,
California
| – | +$18 | +3 | +14% |
|
38
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$83 | +14 | +175% |
|
ELVN Hedge Fund Activity: Q3 2022 in Review
31 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Enliven Therapeutics (ELVN) for Q3 2022, worth a combined $8.78M — up 13% from $7.76M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new ELVN positions and 7 closed out — a net gain of 5 holders — while 4 added to existing stakes and 7 trimmed.
The largest buyer was JBF Capital, opening a new position worth an estimated $310K. The largest seller was NEA Management Company, exiting entirely with an estimated $1.23M sold.
- 31 institutional investors held Enliven Therapeutics (ELVN) as of Q3 2022, up from 26 in Q2 2022.
- Funds reported $8.78M of Enliven Therapeutics stock for Q3 2022, up 13% quarter-over-quarter.
- 12 funds opened new Enliven Therapeutics positions in Q3 2022 and 7 closed out, a net change of +5 holders.
- The largest Enliven Therapeutics buyer in Q3 2022 was JBF Capital, an estimated $310K added.
- The largest Enliven Therapeutics seller in Q3 2022 was NEA Management Company, an estimated $1.23M sold.
Based on aggregated 13F filings for Q3 2022.